ESALF News and Press, Eisai Co Ltd From 07/24/23

2023-07-24 15:08:24 ET Summary Eli Lilly and Company's share price won't stop climbing on the promise of its "miracle" diabetes and weight loss drug, Tirzepatide, and franchise. The share price is +25% so far this year, and +425% over a 5-year period. Lilly is now the world's most...

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 CAMBRIDGE, Mass., and TOKYO, July 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that th...

2023-07-18 08:34:40 ET Summary Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statist...

2023-07-17 13:21:00 ET Complete phase 3 data released on Eli Lilly's ( NYSE: LLY ) donanemab confirmed that the Alzheimer's biologic was effective in slowing cognitive decline in early stages of the disease compared to placebo. Yet, as is the case with Biogen ( BIIB ) and Ei...

Eisai to Present the Latest Alzheimer's Disease Pipeline and Research TOKYO, July 12, 2023 - (JCN Newswire) - Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (A...

2023-07-09 10:00:00 ET Summary The FDA has approved Eisai Co.'s Leqembi label last week, developed with Biogen, for the potential treatment of adult patients with Alzheimer's Disease. The company will lead global development and handle all regulatory submissions for Leqembi, with ...

Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., July 7, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the ...

2023-07-06 18:28:00 ET Quanterix ( NASDAQ: QTRX ) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer's disease, or AD. The diagnostics company said the test allows healthcare profession...

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ven...

Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NO...